Cigna Corp. is testing a pilot program that represents an aggressive move to switch patients from one branded psoriasis drug to another in an effort to cut spending in one of the insurer's most expensive therapeutic categories – inflammatory disease.
Under the new program, Cigna is offering eligible members taking Novartis’ IL-17 inhibitor Cosentyx (secukinumab) a $500 debit card to switch to preferred psoriasis drugs. It is a striking example...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?